Telomerase regulates MYC-driven oncogenesis independent of its reverse transcriptase activity

Journal of Clinical Investigation

Volumn 125, Issue 5, 2015, Pages 2109-2122

  Koh, Cheryl M ^a   Khattar, Ekta ^b   Leow, Shi Chi ^b   Liu, Chia Yi ^b   Muller, Julius ^a   Ang, Wei Xia ^a   Li, Yinghui ^b   Franzoso, Guido ^c   Li, Shang ^d,e   Guccione, Ernesto ^a,e   Tergaonkar, Vinay ^b,e  

^a INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^b AGENCY FOR SCIENCE   (Singapore)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d DUKE NUS MEDICAL SCHOOL   (Singapore)

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

MYC PROTEIN; RNA DIRECTED DNA POLYMERASE; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; MYC PROTEIN, MOUSE; RNA; TELOMERASE RNA; TERT PROTEIN, MOUSE; TUMOR PROTEIN;

ANIMAL CELL; ARTICLE; CANCER CELL; CARCINOGENESIS; CELL CULTURE; CHROMATIN; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME REACTIVATION; GENE REPRESSION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; TELOMERE; UBIQUITINATION; UPREGULATION; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; CANCER TRANSPLANTATION; CELL TRANSFORMATION; DEFICIENCY; ENZYME ACTIVATION; FEEDBACK SYSTEM; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; KNOCKOUT MOUSE; METABOLISM; NONHODGKIN LYMPHOMA; ONCOGENE MYC; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; PROMOTER REGION; PROTEIN PROCESSING; PROTEIN STABILITY; RNA INTERFERENCE; TELOMERE HOMEOSTASIS; TIME; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; ENZYME ACTIVATION; FEEDBACK, PHYSIOLOGICAL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MYC; GLYCOGEN SYNTHASE KINASE 3; HETEROGRAFTS; HUMANS; LYMPHOMA, NON-HODGKIN; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; PHOSPHORYLATION; PROMOTER REGIONS, GENETIC; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN STABILITY; PROTO-ONCOGENE PROTEINS C-MYC; RNA; RNA INTERFERENCE; TELOMERASE; TELOMERE HOMEOSTASIS; TIME FACTORS; TRANSCRIPTION, GENETIC; UBIQUITINATION;

EID: 84929000151     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI79134     Document Type: Article

References (77)

1. Harley CB, Futcher AB, Greider CW. Telomeres shorten during ageing of human fibroblasts. Nature. 1990;345(6274):458-460.
2. Blackburn EH. Switching and signaling at the telomere. Cell. 2001;106(6):661-673.
3. de Lange T. How telomeres solve the end-protection problem. Science. 2009;326(5955):948-952.
4. Teo H, et al. Telomere-independent Rap1 is an IKK adaptor and regulates NF-κB-dependent gene expression. Nat Cell Biol. 2010;12(8):758-767.
5. Greider CW. Molecular biology. Wnt regulates TERT - putting the horse before the cart. Science. 2012;336(6088):1519-1520.
6. Shay JW, Wright WE. Senescence and immortalization: role of telomeres and telomerase. Carcinogenesis. 2005;26(5):867-874.
7. Cong YS, Wright WE, Shay JW. Human telomerase and its regulation. Microbiol Mol Biol Rev. 2002;66(3):407-425.
8. Low KC, Tergaonkar V. Telomerase: central regulator of all of the hallmarks of cancer. Trends Biochem Sci. 2013;38(9):426-434.
9. Li Y, Tergaonkar V. Noncanonical functions of telomerase: implications in telomerase-targeted cancer therapies. Cancer Res. 2014;74(6):1639-1644.
10. Mukherjee S, Firpo EJ, Wang Y, Roberts JM. Separation of telomerase functions by reverse genetics. Proc Natl Acad Sci U S A. 2011;108(50):E1363-E1371.
11. Indran IR, Hande MP, Pervaiz S. hTERT overexpression alleviates intracellular ROS production, improves mitochondrial function, and inhibits ROS-mediated apoptosis in cancer cells. Cancer Res. 2011;71(1):266-276.
12. Gordon DM, Santos JH. The emerging role of telomerase reverse transcriptase in mitochondrial DNA metabolism. J Nucleic Acids. 2010;2010:390791.
13. Kang HJ, et al. Ectopic expression of the catalytic subunit of telomerase protects against brain injury resulting from ischemia and NMDA-induced neurotoxicity. J Neurosci. 2004;24(6):1280-1287.
14. Bodnar AG, et al. Extension of life-span by introduction of telomerase into normal human cells. Science. 1998;279(5349):349-352.
15. Ren JG, Xia HL, Tian YM, Just T, Cai GP, Dai YR. Expression of telomerase inhibits hydroxyl radical-induced apoptosis in normal telomerase negative human lung fibroblasts. FEBS Lett. 2001;488(3):133-138.
16. Park JI, et al. Telomerase modulates Wnt signalling by association with target gene chromatin. Nature. 2009;460(7251):66-72.
17. Ghosh A, et al. Telomerase directly regulates NF-κB-dependent transcription. Nat Cell Biol. 2012;14(12):1270-1281.
18. Masutomi K, et al. The telomerase reverse transcriptase regulates chromatin state and DNA damage responses. Proc Natl Acad Sci U S A. 2005;102(23):8222-8227.
19. Beliveau A, Yaswen P. Soothing the watchman: telomerase reduces the p53-dependent cellular stress response. Cell Cycle. 2007;6(11):1284-1287.
20. Chenette EJ. DNA damage response: Keeping telomerase at bay. Nat Rev Mol Cell Biol. 2009;10(12):813.
21. Tamakawa RA, Fleisig HB, Wong JM. Telomerase inhibition potentiates the effects of genotoxic agents in breast and colorectal cancer cells in a cell cycle-specific manner. Cancer Res. 2010;70(21):8684-8694.
22. Dang CV. MYC on the path to cancer. Cell. 2012;149(1):22-35.
23. Sabò A, Amati B. Genome recognition by MYC. Cold Spring Harb Perspect Med. 2014;4(2):a014191.
24. Walz S, et al. Activation and repression by oncogenic MYC shape tumour-specific gene expression profiles. Nature. 2014;511(7510):483-487.
25. Amati B, Brooks MW, Levy N, Littlewood TD, Evan GI, Land H. Oncogenic activity of the c-Myc protein requires dimerization with Max. Cell. 1993;72(2):233-245.
26. Guccione E, et al. Myc-binding-site recognition in the human genome is determined by chromatin context. Nat Cell Biol. 2006;8(7):764-770.
27. Frank SR, Schroeder M, Fernandez P, Taubert S, Amati B. Binding of c-Myc to chromatin mediates mitogen-induced acetylation of histone H4 and gene activation. Genes Dev. 2001;15(16):2069-2082.
28. Bouchard C, Marquardt J, Bras A, Medema RH, Eilers M. Myc-induced proliferation and transformation require Akt-mediated phosphorylation of FoxO proteins. EMBO J. 2004;23(14):2830-2840.
29. Perna D, et al. Genome-wide mapping of Myc binding and gene regulation in serum-stimulated fibroblasts. Oncogene. 2012;31(13):1695-1709.
30. Gregory MA, Hann SR. c-Myc proteolysis by the ubiquitin-proteasome pathway: stabilization of c-Myc in Burkitt's lymphoma cells. Mol Cell Biol. 2000;20(7):2423-2435.
31. Gregory MA, Qi Y, Hann SR. Phosphorylation by glycogen synthase kinase-3 controls c-myc proteolysis and subnuclear localization. J Biol Chem. 2003;278(51):51606-51612.
32. Zhang X, et al. Mechanistic insight into Myc stabilization in breast cancer involving aberrant Axin1 expression. Proc Natl Acad Sci U S A. 2012;109(8):2790-2795.
33. Salghetti SE, Kim SY, Tansey WP. Destruction of Myc by ubiquitin-mediated proteolysis: cancer-associated and transforming mutations stabilize Myc. EMBO J. 1999;18(3):717-726.
34. Wang X, et al. Phosphorylation regulates c-Myc's oncogenic activity in the mammary gland. Cancer Res. 2011;71(3):925-936.
35. Junttila MR, Westermarck J. Mechanisms of MYC stabilization in human malignancies. Cell Cycle. 2008;7(5):592-596.
36. Cannell IG, et al. p38 MAPK/MK2-mediated induction of miR-34c following DNA damage prevents Myc-dependent DNA replication. Proc Natl Acad Sci U S A. 2010;107(12):5375-5380.
37. Kim HH, Kuwano Y, Srikantan S, Lee EK, Martindale JL, Gorospe M. HuR recruits let-7/RISC to repress c-Myc expression. Genes Dev. 2009;23(15):1743-1748.
38. Greenberg RA, et al. Telomerase reverse transcriptase gene is a direct target of c-Myc but is not functionally equivalent in cellular transformation. Oncogene. 1999;18(5):1219-1226.
39. Choi J, et al. TERT promotes epithelial proliferation through transcriptional control of a Myc- and Wnt-related developmental program. PLoS Genet. 2008;4(1):e10.
40. Sidman CL, Shaffer DJ, Jacobsen K, Vargas SR, Osmond DG. Cell populations during tumorigenesis in Eu-myc transgenic mice. Leukemia. 1993;7(6):887-895.
41. Adams JM, et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature. 1985;318(6046):533-538.
42. Langdon WY, Harris AW, Cory S, Adams JM. The c-myc oncogene perturbs B lymphocyte development in E-mu-myc transgenic mice. Cell. 1986;47(1):11-18.
43. Feldser DM, Greider CW. Short telomeres limit tumor progression in vivo by inducing senescence. Cancer Cell. 2007;11(5):461-469.
44. Yuan X, et al. Presence of telomeric G-strand tails in the telomerase catalytic subunit TERT knockout mice. Genes Cells. 1999;4(10):563-572.
45. Nie Z, et al. c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. Cell. 2012;151(1):68-79.
46. Lin CY, et al. Transcriptional amplification in tumor cells with elevated c-Myc. Cell. 2012;151(1):56-67.
47. Blackwood EM, Eisenman RN. Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. Science. 1991;251(4998):1211-1217.
48. Schneider A, Peukert K, Eilers M, Hanel F. Association of Myc with the zinc-finger protein Miz-1 defines a novel pathway for gene regulation by Myc. Curr Top Microbiol Immunol. 1997;224:137-146.
49. Arabi A, et al. c-Myc associates with ribosomal DNA and activates RNA polymerase I transcription. Nat Cell Biol. 2005;7(3):303-310.
50. Li Z, Boone D, Hann SR. Nucleophosmin interacts directly with c-Myc and controls c-Myc-induced hyperproliferation and transformation. Proc Natl Acad Sci U S A. 2008;105(48):18794-18799.
51. Gonzalez OG, et al. Telomerase stimulates ribosomal DNA transcription under hyperproliferative conditions. Nat Commun. 2014;5:4599.
52. Dang CV. Links between metabolism and cancer. Genes Dev. 2012;26(9):877-890.
53. Bagheri S, et al. Genes and pathways downstream of telomerase in melanoma metastasis. Proc Natl Acad Sci U S A. 2006;103(30):11306-11311.
54. Popov N, Schulein C, Jaenicke LA, Eilers M. Ubiquitylation of the amino terminus of Myc by SCF(β-TrCP) antagonizes SCF(Fbw7)-mediated turnover. Nat Cell Biol. 2010;12(10):973-981.
55. Thomas LR, Tansey WP. Proteolytic control of the oncoprotein transcription factor Myc. Adv Cancer Res. 2011;110:77-106.
56. Adhikary S, et al. The ubiquitin ligase HectH9 regulates transcriptional activation by Myc and is essential for tumor cell proliferation. Cell. 2005;123(3):409-421.
57. Popov N, et al. The ubiquitin-specific protease USP28 is required for MYC stability. Nat Cell Biol. 2007;9(7):765-774.
58. Lutterbach B, Hann SR. Hierarchical phosphorylation at N-terminal transformation-sensitive sites in c-Myc protein is regulated by mitogens and in mitosis. Mol Cell Biol. 1994;14(8):5510-5522.
59. Latil A, et al. htert expression correlates with MYC over-expression in human prostate cancer. Int J Cancer. 2000;89(2):172-176.
60. Verdun RE, Karlseder J. Replication and protection of telomeres. Nature. 2007;447(7147):924-931.
61. Martinez P, Blasco MA. Telomeric and extra-telomeric roles for telomerase and the telomere-binding proteins. Nat Rev Cancer. 2011;11(3):161-176.
62. Chang S, DePinho RA. Telomerase extracurricular activities. Proc Natl Acad Sci U S A. 2002;99(20):12520-12522.
63. Wang J, Xie LY, Allan S, Beach D, Hannon GJ. Myc activates telomerase. Genes Dev. 1998;12(12):1769-1774.
64. Wu KJ, et al. Direct activation of TERT transcription by c-MYC. Nat Genet. 1999;21(2):220-224.
65. Flores I, Evan G, Blasco MA. Genetic analysis of myc and telomerase interactions in vivo. Mol Cell Biol. 2006;26(16):6130-6138.
66. Martinato F, Cesaroni M, Amati B, Guccione E. Analysis of Myc-induced histone modifications on target chromatin. PLoS One. 2008;3(11):e3650.
67. Toyoshima M, et al. Functional genomics identifies therapeutic targets for MYC-driven cancer. Proc Natl Acad Sci U S A. 2012;109(24):9545-9550.
68. Mertz JA, et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci U S A. 2011;108(40):16669-16674.
69. Delmore JE, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011;146(6):904-917.
70. Schmitt CA, Lowe SW. Bcl-2 mediates chemoresistance in matched pairs of primary E(mu)-myc lymphomas in vivo. Blood Cells Mol Dis. 2001;27(1):206-216.
71. Eischen CM, Weber JD, Roussel MF, Sherr CJ, Cleveland JL. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev. 1999;13(20):2658-2669.
72. Migliori V, et al. Symmetric dimethylation of H3R2 is a newly identified histone mark that supports euchromatin maintenance. Nat Struct Mol Biol. 2012;19(2):136-144.
73. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics. 2014;30(15):2114-2120.
74. Langmead B, Trapnell C, Pop M, Salzberg SL. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 2009;10(3):R25.
75. Zhang Y, et al. Model-based analysis of ChIP-Seq (MACS). Genome Biol. 2008; 9(9):R137.
76. Dunning MJ, Smith ML, Ritchie ME, Tavare S. beadarray: R classes and methods for Illumina bead-based data. Bioinformatics. 2007;23(16):2183-2184.
77. Barbosa-Morais NL, et al. A re-annotation pipeline for Illumina BeadArrays: improving the interpretation of gene expression data. Nucleic Acids Res. 2010;38(3):e17.